View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 23, 2021updated 11 Jul 2022 3:10pm

eFFECTOR begins dosing in Phase Ib trial of zotatifin in Covid-19

The safety and tolerability of the IV infusion of the drug candidate are the primary goals.

eFFECTOR Therapeutics has dosed the first participant in the Phase Ib clinical trial of zotatifin (eFT226) to treat outpatients with mild to moderate Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial is funded by a $5m cooperative deal from the US Defense Advanced Research Projects Agency (DARPA) and Defense Health Agency (DHA).

Zotatifin is designed to sequence-selectively block eukaryotic translation initiation factor 4A (eIF4A) mediated translation.

eFFECTOR added that the drug candidate is meant to hinder the translation of messenger ribonucleic acids (mRNAs) that encode various critical oncogenes and survival factors.

The double-blind, randomised, dose-escalation Phase Ib trial will study zotatifin in Covid-19 patients aged 18 to 65 years in an outpatient setting.

It is being carried out in partnership with the University of California, San Francisco (UCSF)’s Quantitative Biosciences Institute (QBI).

The safety and tolerability of the drug candidate are the trial’s primary endpoints.

Secondary goals include the antiviral activity of zotatifin determined as mean change in viral load over time, time to when viral load is not detectable and time to clinical resolution.

Initially, zotatifin will be given in two intravenous (IV) infusions one week apart.

eFFECTOR already completed toxicology and pharmacokinetic studies that showed the exposure and safety of zotatifin’s IV use similar to its subcutaneous use.

The company expects to switch to subcutaneous use, which is considered more favourable for treatment in an outpatient setting.

eFFECTOR Therapeutics president and CEO Steve Worland said: “We believe that positive clinical data from this trial would support the continued development of zotatifin as an antiviral treatment for SARS-CoV-2 and its emerging variants, such as the Delta variant, as well as potential future coronavirus strains that may emerge for which vaccines will be unavailable.”

As the drug candidate targets a human protein called host protein that is needed for viral replication, it could be less prone to resistance from viral mutations compared to therapies acting on virus-encoded proteins, Worland added.

In addition to Covid-19, zotatifin is being studied in a Phase I/II trial for solid tumours treatment.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena